Drugs / SC-003
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02539719 | Aug 2015 → Jan 2019 | ovarian cancer | Stemcentrx | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02539719 ↗ |
| Known as | Tamrintamab pamozirine | “Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.” PMID 32513564 ↗ Jun 2020 |
| Route | Intravenous | “Phase 1a (Escalation) - IV infusion Phase 1b (Expansion) - IV infusion” NCT02539719 ↗ |
| Target | DPEP3 | “targeting dipeptidase 3 (DPEP3)” PMID 32513564 ↗ Jun 2020 |